This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
This report presents the results of a systematic literature review investigating the impact of novel strategies and approaches (using existing and/or novel testing technologies) on access to testing, testing coverage, and linkage to care of key populations at-risk for sexually transmitted infections (STIs).
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
This report aims to identify and evaluate the operational challenges each country is facing in implementing vector control and to prioritise the needs to be addressed in order to facilitate national public health authorities in developing and/or enhancing their national WNV response capacities.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.